Show simple item record

dc.contributor.authorBarei, Fereshteh*
dc.contributor.authorLe Pen, Claude*
dc.contributor.authorSimoens, Steven*
dc.date.accessioned2013-04-09T12:00:23Z
dc.date.available2013-04-09T12:00:23Z
dc.date.issued2012
dc.identifier.urihttps://basepub.dauphine.fr/handle/123456789/11198
dc.language.isoenen
dc.subjectCompetition strategyen
dc.subjectproduct portfolioen
dc.subjectre-innovationen
dc.subjectsuper genericsen
dc.subjecttechnology platformsen
dc.subject.ddc334en
dc.subject.classificationjelI.I1.I12en
dc.subject.classificationjelO.O3.O32en
dc.subject.classificationjelL.L6.L65en
dc.titleFrom generic to biosimilar drugs: why take an innovative pace?en
dc.typeArticle accepté pour publication ou publié
dc.description.abstractenBACKGROUND: The transition of the generic/biotechnology industry to innovation by investing in innovative R&D will enhance business expertise in biopharmaceutical development and manufacturing. The major impact of this evolution is on patient access to treatment and savings for the health care systems. OBJECTIVES: The aim of this paper is to investigate the innovative aspect of biosimilar and biobetter products, manufactured by some big generic companies. We will also try to explore the innovative business strategy, implementing this high risk product differentiation policy. METHODS: This qualitative research is conducted by a series of interviews with CEOs, physicians, and academics in different countries. The qualitative data obtained were analyzed by Nvivo9.2 software. A literature review has also contributed to our key findings. RESULTS: The results show that switching into biosimilars/biobetters is an innovative strategic choice, approved by some big generic pharmaceutical companies. The biosimilar/biobetter products can be considered innovative because of their value added quality. CONCLUSION: Expanding the product portfolio to biosimilars/biobetter can be considered as a long run strategy in the innovative business plans aiming to ensure the market access. Patients and their access to better treatments are major components of these innovative business models.en
dc.relation.isversionofjnlnameFarmeconomia e percorsi terapeutici
dc.relation.isversionofjnlvol13en
dc.relation.isversionofjnlissue3Sen
dc.relation.isversionofjnldate2012
dc.relation.isversionofjnlpages21-27en
dc.relation.isversionofjnlpublisherSEEd Medical Publishersen
dc.subject.ddclabelEconomie socialeen
dc.relation.forthcomingnonen
dc.relation.forthcomingprintnonen
dc.description.halcandidateoui
dc.description.readershiprecherche
dc.description.audienceInternational
dc.relation.Isversionofjnlpeerreviewedoui
hal.person.labIds255365*
hal.person.labIds255365*
hal.person.labIds460568*
hal.identifierhal-01507559*


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record